<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01081392</url>
  </required_header>
  <id_info>
    <org_study_id>CIA-01.2</org_study_id>
    <nct_id>NCT01081392</nct_id>
  </id_info>
  <brief_title>Inflammatory Markers in Sputum After LPS Inhalation</brief_title>
  <official_title>The Role of Inhaled Particle Size on the Inflammatory Response Induced by Endotoxin Inhalation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire Brugmann</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire Brugmann</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to measure inflammatory biomarkers in sputum and peripheral blood
      in healthy volunteers after inhalation of single doses of LPS (20 mcg) administered as
      particles of different sizes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Endotoxins are inflammatory substances present in the environment. In man, the inhalation of
      the lipopolysaccharride moiety (LPS) induces measurable immune responses. With an inhaled
      single dose of 20 micron, the inflammatory response in man is sub-clinical. During
      bronchoprovocation tests with allergens, the particle size determines to a large extent the
      intensity of the response. the response to LPS as a function of particle size is not known
      and will be studied in this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>January 2010</start_date>
  <completion_date type="Anticipated">May 2010</completion_date>
  <primary_completion_date type="Anticipated">April 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Absolute neutrophil count in sputum</measure>
    <time_frame>24hrs after LPS inhalation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>white blood cells and differential in peripheral blood</measure>
    <time_frame>0, 6 and 24 hrs after LPS inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CC16 in peripheral blood</measure>
    <time_frame>0, 6 and 24hrs after LPS inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Calgranulin A/B</measure>
    <time_frame>0, 6 and 24hrs after LPS inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CRP in peripheral blood</measure>
    <time_frame>0, 6 and 24hrs after LPS inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spirometry (FEV1 and FEV1/FEV)</measure>
    <time_frame>0, 1, 6 and 24hrs after LPS inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Alveolo-capillary diffusion</measure>
    <time_frame>0, 6 and 24hrs after LPS inhalation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>12-lead ECG</measure>
    <time_frame>Screening Visit 1 and final Visit 5</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical exam</measure>
    <time_frame>At the Screening Visit 1, at the three Visits with LPS inhalation and at the Final Visit</time_frame>
    <description>A complete physical exam at screening and at the final Visits, and an abbreviated physical exam at the three Visits during which LPS will be administered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety labs from peripheral blood</measure>
    <time_frame>At the Screening Visit 1 and the Final Visit 5</time_frame>
    <description>hematology, blood chemistry (ionogram, AST, ALT, alkaline phosphatases, urea, creatinine)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>LPS sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulizers A then B then C</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulizers B then C then A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulizers C then A then B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulizers A then C then B</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS sequence 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulizers C then B then A</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LPS sequence 6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nebulizers B then A then C</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>LPS</intervention_name>
    <description>LPS 20mcg sd inhaled via nebulizer, 3 periods</description>
    <arm_group_label>LPS sequence 1</arm_group_label>
    <arm_group_label>LPS sequence 2</arm_group_label>
    <arm_group_label>LPS sequence 3</arm_group_label>
    <arm_group_label>LPS sequence 4</arm_group_label>
    <arm_group_label>LPS sequence 5</arm_group_label>
    <arm_group_label>LPS sequence 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy volunteer, non-smoking or ex-smoker &gt;1mth and &lt;10packs/year

          -  normal ECG

          -  normal lab values for hematology, ionogram, AST, ALT, alk phosphatases, urea,
             creatinine and CRP

          -  FEV1/forced vital capacity &gt;0.7 and FEV1&gt;80% of predicted value

          -  able to produce valid sputum following induction (&gt;=50% viable cells, &lt;50% squamous
             cells and &lt;60% neutrophils)

          -  females must be using contraception

          -  written informed consent

        Exclusion Criteria:

          -  infection within 14 days

          -  history of bronchial asthma

          -  obstructive respiratory condition with FEV1 &lt;70% of theoretical value
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olivier MICHEL, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Brugmann</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHU Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 2, 2010</study_first_submitted>
  <study_first_submitted_qc>March 4, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2010</study_first_posted>
  <last_update_submitted>March 4, 2010</last_update_submitted>
  <last_update_submitted_qc>March 4, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jean-Pierre Tassignon, MD, PhD, Head Clinical Research Unit</name_title>
    <organization>CHU Brugmann</organization>
  </responsible_party>
  <keyword>LPS</keyword>
  <keyword>endotoxin</keyword>
  <keyword>inflammatory markers</keyword>
  <keyword>healthy volunteers</keyword>
  <keyword>neutrophils in sputum</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

